Segui
Francesco Cognetti
Francesco Cognetti
Direttore Oncologia Medica 1 IFO Istituto Nazionale Tumori Regina Elena Roma
Email verificata su ifo.it
Titolo
Citata da
Citata da
Anno
Nivolumab in previously untreated melanoma without BRAF mutation
C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ...
New England journal of medicine 372 (4), 320-330, 2015
59932015
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
New England Journal of Medicine 371 (23), 2167-2177, 2014
35582014
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
J Bernier, C Domenge, M Ozsahin, K Matuszewska, JL Lefèbvre, ...
New England Journal of Medicine 350 (19), 1945-1952, 2004
33502004
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast …
M Marty, F Cognetti, D Maraninchi, R Snyder, L Mauriac, M Tubiana-Hulin, ...
Journal of clinical oncology 23 (19), 4265-4274, 2005
20132005
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised …
E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ...
The lancet oncology 18 (9), 1274-1284, 2017
16452017
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non–small-cell lung cancer
GV Scagliotti, R Fossati, V Torri, L Crino, G Giaccone, G Silvano, ...
Journal of the National Cancer Institute 95 (19), 1453-1461, 2003
8152003
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
6402017
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
L Serrone, M Zeuli, FM Sega, F Cognetti
Journal of experimental & clinical cancer research: CR 19 (1), 21-34, 2000
5202000
PTEN: multiple functions in human malignant tumors
M Milella, I Falcone, F Conciatori, U Cesta Incani, A Del Curatolo, ...
Frontiers in oncology 5, 24, 2015
5042015
Cancer in the elderly: why so badly treated?
IS Fentiman, U Tirelli, S Monfardini, M Schneider, J Festen, F Cognetti, ...
The Lancet 335 (8696), 1020-1022, 1990
4451990
Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy
A Pace, A Savarese, M Picardo, V Maresca, U Pacetti, G Del Monte, ...
Journal of Clinical Oncology 21 (5), 927-931, 2003
4152003
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis
A Alimonti, C Nardella, Z Chen, JG Clohessy, A Carracedo, LC Trotman, ...
The Journal of clinical investigation 120 (3), 681-693, 2010
4132010
Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
D Del Bufalo, L Ciuffreda, D Trisciuoglio, M Desideri, F Cognetti, G Zupi, ...
Cancer research 66 (11), 5549-5554, 2006
4032006
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
F Roila, M Tonato, F Cognetti, E Cortesi, G Favalli, M Marangolo, ...
Journal of Clinical Oncology 9 (4), 675-678, 1991
3601991
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic …
M Clavel, JB Vermorken, F Cognetti, P Cappelaere, PHM De Mulder, ...
Annals of oncology 5 (6), 521-526, 1994
3461994
Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial
PA Ascierto, GV Long, C Robert, B Brady, C Dutriaux, AM Di Giacomo, ...
JAMA oncology 5 (2), 187-194, 2019
3422019
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double …
A Poveda, A Floquet, JA Ledermann, R Asher, RT Penson, AM Oza, ...
The Lancet Oncology 22 (5), 620-631, 2021
2792021
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with …
H Roché, L Yelle, F Cognetti, L Mauriac, C Bunnell, J Sparano, P Kerbrat, ...
Journal of clinical oncology 25 (23), 3415-3420, 2007
2762007
Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial
A Pace, D Giannarelli, E Galie, A Savarese, S Carpano, M Della Giulia, ...
Neurology 74 (9), 762-766, 2010
2462010
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian …
F Cognetti, EM Ruggeri, A Felici, M Gallucci, G Muto, CF Pollera, ...
Annals of oncology 23 (3), 695-700, 2012
2442012
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20